Interleukin family member ST2 and mortality in acute dyspnoea
Open Access
- 15 July 2010
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 268 (5), 493-500
- https://doi.org/10.1111/j.1365-2796.2010.02263.x
Abstract
Socrates T, deFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M, Potocki M, Reiter M, Arenja N, Heinisch C, Meissner J, Jaeger C, Christenson R, Mueller C. (Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; University of Maryland, School of Medicine, Baltimore, MD, USA). Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 2010; 268: 493–500. Objectives. The study objective was to investigate the prognostic utility and patient‐specific characteristics of ST2 (suppression of tumorigenicity 2), assessed with a novel sensitive assay. Background. Suppression of tumorigenicity 2 signalling has been shown to be associated with death in cardiac and pulmonary diseases. Design/Subjects. In an international multicentre cohort design, we prospectively enrolled 1091 patients presenting with acute dyspnoea to the emergency department (ED). ST2 was measured in a blinded fashion using a novel assay and compared to B‐type natriuretic peptide (BNP) and NT‐proBNP. The primary end‐point was mortality within 30 days and 1 year. The prognostic value of ST2 was evaluated in comparison and in addition to BNP and NT‐proBNP. Results. Suppression of tumorigenicity 2 concentrations was higher amongst decedents than among survivors (median 85 vs. 43 U mL−1, P < 0.001) and also higher in patients with impaired left ventricular ejection fraction (LVEF) when compared with preserved LVEF (P < 0.001). In receiver operator characteristics analysis, the area under the curve (AUC) for ST2, BNP and NT‐proBNP to predict 30‐day and 1‐year mortality were 0.76, 0.63 and 0.71, and 0.72, 0.71 and 0.73, respectively. The combinations of ST2 with BNP or NT‐proBNP improved prediction of mortality provided by BNP or NT‐proBNP alone. After multivariable adjustment, ST2 values above the median (50 U mL−1) significantly predicted 1‐year mortality (HR 2.3, P < 0.001). Conclusion. In patients presenting to the ED with acute dyspnoea, ST2 is a strong and independent predictor of 30‐day and 1‐year mortality and might improve risk stratification already provided by BNP or NT‐proBNP.Keywords
This publication has 34 references indexed in Scilit:
- Low-Risk Acute Heart Failure PatientsCritical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2009
- Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational studyCritical Care, 2009
- Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart FailureJournal of Cardiac Failure, 2008
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJournal of the American College of Cardiology, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute DyspneaClinical Chemistry, 2007
- Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)American Heart Journal, 2006
- Predictors of Elevated B-Type Natriuretic Peptide Concentrations in Dyspneic Patients Without Heart Failure: An Analysis From the Breathing Not Properly Multinational StudyAnnals of Emergency Medicine, 2005
- Preliminary Evaluation of the AxSYM B-Type Natriuretic Peptide (BNP) Assay and Comparison with the ADVIA Centaur BNP AssayClinical Chemistry, 2004
- Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute DyspneaThe New England Journal of Medicine, 2004